Pluri (NASDAQ:PLUR – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Volatility and Risk
Pluri has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
Insider & Institutional Ownership
16.6% of Pluri shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Pluri and AbCellera Biologics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $1.02 million | 13.85 | -$23.82 million | ($2.45) | -0.46 |
| AbCellera Biologics | $75.13 million | 50.85 | -$146.41 million | ($0.54) | -23.07 |
Pluri has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Pluri and AbCellera Biologics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
| AbCellera Biologics | 1 | 1 | 6 | 2 | 2.90 |
AbCellera Biologics has a consensus target price of $16.33, suggesting a potential upside of 31.09%. Given AbCellera Biologics’ stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Pluri.
Profitability
This table compares Pluri and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -2,344.59% | N/A | -82.71% |
| AbCellera Biologics | -248.83% | -17.49% | -12.36% |
Summary
AbCellera Biologics beats Pluri on 11 of the 15 factors compared between the two stocks.
About Pluri
Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
